var data={"title":"Histrelin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Histrelin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6315?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=histrelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Histrelin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=histrelin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Histrelin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179193\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Supprelin LA;</li>\n      <li>Vantas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934287\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vantas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179209\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist;</li>\n      <li>\n        Gonadotropin Releasing Hormone Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179195\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prostate cancer, advanced (Vantas):</b> SubQ: 50 mg implant surgically inserted every 12 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5025514\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=histrelin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Histrelin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Central precocious puberty (Supprelin LA):</b> Children &ge;2 years: SubQ: 50 mg implant surgically inserted every 12 months. Discontinue at the appropriate time for the onset of puberty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179196\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179197\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vantas: CrCl &ge;15 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Supprelin LA: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25709218\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179173\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Supprelin LA: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vantas: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179161\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50133910\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supprelin LA <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022058s014s015lbl.pdf#page=19&amp;token=XpnPwCrTT6lhacUEfwI0dFfs0LmHR9LKK9W5Ty130UeMPKko0wh2RL0qSPBP9SHEAqtl8FysiTBc6GuXKgOGUxdAh9xCLgZwTDkwSqPTVLenHLw8iIndZdqi16fPSug4&amp;TOPIC_ID=8753\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022058s014s015lbl.pdf#page=19</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179176\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Surgical implantation (using a sterile field) into the inner portion of the upper arm requires the use of the implantation device provided. Do not bend or pinch the implant. Use the patient's nondominant arm for placement; implant should be placed halfway between the shoulder and the elbow at the crease between the tricep and the bicep. Implant removal should occur after ~12 months; a replacement implant may be inserted if therapy is to be continued. Palpate area of incision to locate implant for removal. If not readily palpated, ultrasound, CT, or MRI may be used to locate implant; plain films are not recommended because the implant is not radiopaque. Refer to manufacturer's labeling for full insertion and removal details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132616\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (when dosage form allows) closed system transfer devices (CSTDs) for compounding. Double gloving and a protective gown are recommended during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179175\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central precocious puberty (Supprelin LA):</b> Treatment of children with central precocious puberty</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced (Vantas):</b> Palliative treatment of advanced prostate cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179165\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CPP:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Dermatologic: Dermatological reaction (51%; insertion site reaction includes bruise, discomfort, erythema, pain, protrusion of implant area, pruritus, soreness, swelling, tingling)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Emotional lability (&le;2%), headache (&le;2%), migraine (&le;2%), sensation of cold (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Scarring (6%), pruritus (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gynecomastia (&le;2%), hypermenorrhea (&le;2%), weight gain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Uterine hemorrhage (4%), breast tenderness (&le;2%), dysmenorrhea (&le;2%), precocious puberty (&le;2%; progression of central precocious puberty)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Pituitary neoplasm (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Localized infection (&le;2%; implant site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Keloid-like scar (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (&le;2%), flu-like symptoms (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Procedural complications (6%; suture-related), postoperative pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Endocrine &amp; metabolic: Altered hormone levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1%, postmarketing, and/or case reports: Aggressive behavior, amblyopia, crying, device expulsion, hostility, irritability, seizure, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatological reaction (3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (66%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (&lt;2%), palpitations (&lt;2%), peripheral edema (&lt;2%), ventricular premature contractions (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (10%), headache (3%), insomnia (3%), depression (&lt;2%), dizziness (&lt;2%), irritability (&lt;2%), lethargy (&lt;2%), malaise (&lt;2%), pain (&lt;2%), sensation of cold (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&lt;2%), genital pruritus (&lt;2%), hypotrichosis (&lt;2%), night sweats (&lt;2%), pruritus (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gynecomastia (4%), decreased libido (2%), weight gain (2%), fluid retention (&lt;2%), hypercalcemia (&lt;2%), hypercholesterolemia (&lt;2%), increased lactate dehydrogenase (&lt;2%), increased prostatic acid phosphatase (&lt;2%), increased serum glucose (&lt;2%), weight loss (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (4%), abdominal distress (&lt;2%), food cravings (&lt;2%), increased appetite (&lt;2%), nausea (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Testicular atrophy (5%; expected pharmacological consequence of testosterone suppression), erectile dysfunction (4%), breast tenderness (&lt;2%), dysuria (&lt;2%), exacerbation of gynecomastia (&lt;2%), exacerbation of hematuria (&lt;2%), exacerbation of urinary frequency (&lt;2%), hematuria (&lt;2%), mastalgia (&lt;2%), urinary frequency (&lt;2%), urinary retention (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&lt;2%), bruise (&lt;2%), hematoma (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic disease (&lt;2%), increased serum AST (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bruising at injection site (7%), pain at injection site (&le;4%), tenderness at injection site (&le;4%), erythema at injection site (3%), inflammation at injection site (1%), injection site infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), back pain (&lt;2%), exacerbation of back pain (&lt;2%), limb pain (&lt;2%), muscle twitching (&lt;2%), myalgia (&lt;2%), neck pain (&lt;2%), ostealgia (&lt;2%), tremor (&lt;2%), weakness (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (5%), decreased creatinine clearance (&lt;2%), exacerbation of renal failure (&lt;2%), nephrolithiasis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea on exertion (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Stent occlusion (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Decreased bone mineral density, hepatic injury (severe), increased testosterone level, swelling at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179179\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to histrelin acetate, gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, or any component of the formulation; females who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179163\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). An increased risk of MI, sudden cardiac death, and stroke has been reported with GnRH agonist use in men; monitor for symptoms associated with cardiovascular disease. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval, or with pre-existing cardiac disease. Consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Hyperglycemia has been reported with androgen deprivation therapy (in prostate cancer) and may manifest as diabetes or worsening of preexisting diabetes. Monitor blood glucose and/or HbA<sub>1c</sub>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently, cardiovascular collapse; immediate medical attention required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric events: Psychiatric events have been described with GnRH agonists, including histrelin; symptoms of emotional lability, irritability, impatience, anger, and aggression have been reported in postmarketing accounts. Monitor for development or worsening of psychiatric symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been reported in patients receiving GnRH agonists, including histrelin. Reports have occurred in patients with a history of seizures, epilepsy, cerebrovascular disorders, CNS anomalies, or tumors, and patients on concomitant medications associated with seizures (eg, bupropion, SSRIs). Seizures have also been reported in patients without underlying conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal cord compression: Has been reported, may contribute to paralysis when used for prostate cancer; closely observe patients with metastatic vertebral lesions for weakness and paresthesias in first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor flare: Transient increases in serum testosterone (in men with prostate cancer) occur during the first week of use and may result in a worsening of disease signs and symptoms (bone pain, neuropathy, hematuria, ureteral/bladder outlet obstruction, spinal cord compression) during the first week of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Ureteral obstruction may occur when used for prostate cancer; closely observe patients for urinary tract obstruction or poor urine output in first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Worsening of symptoms: Transient increases in estradiol serum levels (female) or testosterone levels (female and male) may occur during the first week of use for central precocious puberty (CPP); however, manifestations of puberty should decrease within 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Implant complications: Proper surgical insertion technique is essential to avoid complications. Patients should keep arm dry for 24 hours and avoid heavy lifting/strenuous exertion of insertion arm for 7 days after implantation. In prostate cancer studies, the implant was not recovered in a small number of patients. Serum testosterone rose above castrate level and the implant was not palpable or visualized (via ultrasound); it was believed to have been extruded. Some patients had continued testosterone levels below castration level even though the implant was not palpable. If the implant breaks during removal in children with CPP, the remaining pieces should be removed; confirm the removal of the entire implant (refer to manufacturer's instructions for removal procedure).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299447\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179166\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8753&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179169\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179180\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Histrelin is contraindicated for use during pregnancy or in women who may become pregnant. Adverse events were observed in animal reproduction studies. May cause fetal harm or spontaneous abortion if administered during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5025538\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if histrelin is present in breast milk. The products are not indicated for use in postpubertal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179171\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central precocious puberty (CPP): Luteinizing hormone, follicle-stimulating hormone, estradiol, or testosterone (after 1 month then every 6 months); height, bone age (every 6 to 12 months); Tanner staging; monitor for clinical evidence of suppression of CPP manifestations; monitor for development or worsening of psychiatric symptoms, including depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostate cancer: Serum testosterone levels, prostate specific antigen (PSA); bone mineral density; weakness, paresthesias, and urinary tract obstruction (especially during first few weeks of therapy); screen for diabetes; monitor for symptoms associated with cardiovascular disease. Consider periodic monitoring of electrocardiograms and electrolytes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179174\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Prostate cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Testosterone level: Expected to rise during the first few days and decline to below initiation level by week 2 before reaching &le;50 ng/dL (castrate level) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">PSA: Expected to decrease to normal levels after 6 months of therapy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Lack of response (testosterone and PSA decreases) should prompt suspicion that the implant has been expelled.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179162\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent inhibitor of gonadotropin secretion; continuous administration results in, after an initiation phase, the suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and a subsequent decrease in testosterone and dihydrotestosterone (males) and estrone and estradiol (premenopausal females). Testosterone levels are reduced to castrate levels in males (treated for prostate cancer) within 2 to 4 weeks. Additionally, in patients with CPP, linear growth velocity is slowed (improves chance of attaining predicted adult height). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179178\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Prostate cancer: Chemical castration: Within 2 to 4 weeks; CPP: Progression of sexual development stops and growth is decreased within 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 12 months (plus a few additional weeks of histrelin release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Adults: V<sub>d</sub>: ~58.4 L &plusmn; 7.86 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Adults: ~70% &plusmn; 9%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via C-terminal dealkylation and hydrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Adults: SubQ: 92%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Terminal: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Adults: 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323184\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Supprelin LA Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $35,377.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Vantas Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $4,401.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301435\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vantas (AR, BG, CH, CZ, DE, DK, EE, FI, FR, LT, MY, NO, PL, RO, SE, SG, SI, TH);</li>\n      <li>Vantasse (BE, NL);</li>\n      <li>Vantus (HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dineen MK, Tierney DS, Kuzma P, et al, &ldquo;An Evaluation of the Pharmacokinetics and Pharmacodynamics of the Histrelin Implant for the Palliative Treatment of Prostate Cancer,&rdquo; <i>J Clin Pharmacol</i>, 2005, 45(11):1245-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/16239357/pubmed\" target=\"_blank\" id=\"16239357\">16239357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahhal S, Clarke WL, Kletter GB, et al, &quot;Results of a Second Year of Therapy With the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty,&quot; <i>Int J Pediatr Endocrinol</i>, 2009, 2009:812517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/19956699/pubmed\" target=\"_blank\" id=\"19956699\">19956699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlegel PN, Histrelin Study Group, &ldquo;Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer,&rdquo; <i>J Urol</i>, 2006, 175(4):1353-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/16515997/pubmed\" target=\"_blank\" id=\"16515997\">16515997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shore N, Cookson MS, and Gittelman MC, &ldquo;Long-Term Efficacy and Tolerability of Once-Yearly Histrelin Acetate Subcutaneous Implant in Patients With Advanced Prostate Cancer,&rdquo; <i>BJU Int</i>, 2012, 109(2):226-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-drug-information/abstract-text/21851539/pubmed\" target=\"_blank\" id=\"21851539\">21851539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Supprelin LA (histrelin acetate) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vantas (histrelin) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; June 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8753 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179193\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934287\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F179209\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F179195\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5025514\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F179196\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F179197\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25709218\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179173\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F179161\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50133910\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F179176\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132616\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F179175\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179165\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179179\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179163\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299447\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179166\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179169\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F179180\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5025538\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F179171\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F179174\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179162\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F179178\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323184\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301435\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8753|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=histrelin-patient-drug-information\" class=\"drug drug_patient\">Histrelin: Patient drug information</a></li><li><a href=\"topic.htm?path=histrelin-pediatric-drug-information\" class=\"drug drug_pediatric\">Histrelin: Pediatric drug information</a></li></ul></div></div>","javascript":null}